MemorialCare Announces Plans for New Dimensions in Telehealth
MemorialCare, a California nonprofit health system and a Healthcare Leadership Council member, has announced it is offering on-demand, remote medical exams powered by artificial intelligence that will enable physicians to provide patients with enhanced remote care involving in-depth physical examinations.
Through a partnership with TytoCare, patients will use an FDA-cleared handheld examination kit to perform comprehensive physical exams of the heart, skin, ears, throat, abdomen, and lungs, and measure heart rate and body temperature, which are key for treating many acute and chronic conditions. During one of these appointments, MemorialCare providers can diagnose and treat conditions as well as provide a prescription, if needed. Exam data is sent via an encrypted, secure network and stored on MemorialCare's HIPAA-compliant cloud.
Barry Arbuckle, Ph.D, president and CEO of MemorialCare said, "MemorialCare is committed to finding ways to enable patients to manage their health through a personalized healthcare experience and ensure that no matter their circumstance, they have easy access to clinic-quality examinations from the comfort of home."
Data Presented by Guardant Health Shows Blood Test Highly Accurate in Detecting Multiple Cancers
Guardant Health, a leading precision oncology company and a Healthcare Leadership Council member, recently announced new data demonstrating the ability of the company's investigational next-generation multi-cancer assay to accurately detect early-stage cancers. Guardant SHIELD is designed to analyze approximately 20,000 epigenomic biomarkers that are informative for detection of a wide range of solid tumors in a single blood test.
Data from a presentation at the American Association for Cancer Research Annual Meeting showed the next-generation Guardant SHIELD multi-cancer screening assay achieved detection rates of 90 percent in stages I and II colorectal cancer and 87 percent in stages I and II lung cancer. Current screening options for these cancers, while effective, are limited due to low compliance rates - 66 percent for colorectal cancer and 14 percent for lung cancer. A high performance blood test that can be completed as part of a routine patient workup has the potential to improve screening rates and, ultimately, save more lives.
Guardant Health co-CEO AmirAli Talasaz said, "These positive results show that the next-generation Guardant SHIELD multi-cancer assay provides sensitive detection of early-stage cancers with the ability to identify the tumor tissue of origin with high accuracy. Presentation of these positive results represents a major step forward in our commitment to offering clinicians and patients a highly sensitive blood-based multi-cancer screening test in select tumor types where we believe cancer screening can save lives."